CN106729641A - Composition and its application - Google Patents
Composition and its application Download PDFInfo
- Publication number
- CN106729641A CN106729641A CN201611220181.4A CN201611220181A CN106729641A CN 106729641 A CN106729641 A CN 106729641A CN 201611220181 A CN201611220181 A CN 201611220181A CN 106729641 A CN106729641 A CN 106729641A
- Authority
- CN
- China
- Prior art keywords
- composition
- cell
- group
- umbilical cord
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to cell field, more particularly to composition and its application.Said composition includes growth factor, albumin and umbilical cord mesenchymal stem cells.Said composition can prevent hepatic failure, slow down chronic liver failure is in progress and removes harmful toxicity.This cell composition is for preventing and/or treating as ischaemic, medicine as being effective to second phthalein amino phenols, virus, obesity nonalcoholic fatty liver disease and obstruction bile duct obstruction, the chronic liver injury caused by tumour.
Description
Technical field
The present invention relates to cell field, more particularly to composition and its application.
Background technology
Hepatic failure is that the major Liver that many factors cause is damaged, and causes the work(such as its synthesis, removing toxic substances, excretion and bioconversion
Serious hindrance or decompensation can occur, it is the one of main performance to occur with coagulation function obstacle and yellow subcutaneous ulcer, hepatic encephalopathy, ascites etc.
Group clinical syndrome.In the last few years, because the dead number of hepatic failure gradually increases, according to statistics, it is dead that the U.S. there are about ten thousand people every year
In liver failure, and China dies from the patient Yue Wan of this disease every year.Acute hepatic failure is a kind of acute serious liver function energy barrier
Hinder, be characterized in that onset is anxious, the state of an illness is critical, Symptoms are various, liver cell extensive necrosis.The primary hand of hepatic failure is treated at present
Section is medical treatment, liver transfer operation and cell therapy etc..Medical treatment offer limited effectiveness, not yet there is specific drug to the ill so far.
At present, though liver transfer operation turned into treatment End-stage liver disease important means, donor shortage, surgical injury, immunological rejection and
The problems such as high cost, constitutes the major obstacle of Technology of Liver Transplantation in China development.Therefore, carrying out has invasive small, few intercurrent disease etc.
The study hotspot stem cell that the stem cell transplantation of feature turns into treatment acute hepatic failure recently is a kind of undifferentiated cell, there is two
Essential characteristic, one is the of self-replication capacity, and two is that can be divided into more than one functioning cell, according to the size of differentiation potential,
Stem cell is broken generally into three classes, and the first kind is that myeloid-lymphoid stem cell can be categorized as the consistent totipotent cell of function.Equations of The Second Kind is
Pluripotent stem cell, it can break up as every kind of cell type in body, but can not be formed placenta and development of fetus institute it is necessary
Supporting tissue.3rd class is that adult stem cell is a kind of stem cell that will possess lifelong self-replacation or self-renewal capacity.
It is all kinds cell that it is distributed in different tissues and can form.
Mescenchymal stem cell, belongs to adult stem cell, be it is a kind of with the of self-replication capacity and multi-lineage potential into
Somatic stem cell, belongs to non-terminally differentiated cells, can be divided into fat, cartilage, bone, muscle, flesh leg, nerve, liver, cardiac muscle, pancreas islet
The Various Tissues cell such as cell and endothelium.Mescenchymal stem cell is low due to immunogenicity, and adult tissue's abundance is widely present
Marrow, adipose tissue, neonatal umbilical cord and placenta in human body etc., it is easy to separate, purity is high, during negative for tumor cells pollution amplification
Cultivating system can be unified, and be easy to Quality Control to can be made into seed cell and freeze, and be used for multiple times, the small latent virus of loss cell after freezing
To puerpera and neonate without any harm and damage collection side during with the infection of pathogenic microorganism and propagation probability than relatively low collection
Just, it is easy to storage and transport, ethics dispute is few.Many researchs at present have shown that stem cell entered specific culture and has point in vitro
It is melted into the ability for liver cell.
In recent years umbilical cord source mescenchymal stem cell, treatment because its have favorable reproducibility, low immunogenicity, expense it is low, fortune
Make the advantage such as convenient, easy, as the effective ways after another treatment hepatic failure after orthotopic liver transplantation.Preparation process is relatively simple
It is single, be easy to collect, it is biological nature stabilization, security performance stabilization, reproducible, patient can psychologically receive, therefore can be completely
The demand of sufficient clinical practice.Multiplication capacity is strong, and there is adherence quality to be conducive to the purifying and culture of cell for it, while having stronger
Differentiation capability, immunogenicity are low, avoid embryo stem cell transplantation after there may be teratoma and ethics problem；It can be different
Gene transplant long-term survival simultaneously plays normal physiological function, therefore new treatment method one has greatly excellent in treatment
Gesture.
Many researchs at present have shown that stem cell entered specific culture and has ability of the differentiation as liver cell in vitro.Prove
Candidate stem cell be able to can be broken up as liver cell with vitro culture.Research has shown that the derived mesenchymal stem cells in vitro point of derived from bone marrow
Changing culture can break up hepatoblast.The relevant experimental model of current rat, mouse and people, points out bone marrow-derived cells to turn
Turn to liver cell.The current report on separate sources stem-cell therapy acute hepatic failure also has a lot.Prove that umbilical cord mesenchyma is done
Cell can treat the acute hepatic failure caused to second phthalidyl amino phenols.Someone draws a conclusion, and some partial injuries may be more in liver
It is adapted to be repaired with the stem cell of derived from bone marrow.
The research of bone mesenchymal stem cells treatment acute hepatic failure is also had been reported that, but mesenchymal stem cells MSCs was drawn materials
Journey is caused compared with major injury to patient, also there is that induction occurs fatty liver with fat mesenchymal stem cell.
The content of the invention
In view of this, the present invention provides a kind of composition and its application.Said composition can prevent hepatic failure, slow down chronic
Hepatic failure is in progress and removes harmful toxicity.This cell composition is for preventing and/or treating by ischaemic, medicine such as to second
Phthalein amino phenols, virus, obesity nonalcoholic fatty liver disease and the Chronic Liver blocked caused by bile duct obstruction, tumour are damaged
Wound is effective.
In order to realize foregoing invention purpose, the present invention provides following technical scheme：
The invention provides a kind of composition, including growth factor, albumin and umbilical cord mesenchymal stem cells.
In some specific embodiments of the invention, growth factor described in the composition accounts for the quality hundred of composition
Content is divided to be 1~10%.
In some specific embodiments of the invention, growth factor described in the composition accounts for the quality hundred of composition
Content is divided to be 5%.
In some specific embodiments of the invention, albumin described in the composition accounts for the quality percentage of composition
Content is 15~30%.
In some specific embodiments of the invention, albumin described in the composition accounts for the quality percentage of composition
Content is 20%.
In some specific embodiments of the invention, the concentration of umbilical cord mesenchymal stem cells is described in the composition
1.0~10.0 × 107/ml。
In some specific embodiments of the invention, the concentration of umbilical cord mesenchymal stem cells is described in the composition
1.5×107/ml。
In some specific embodiments of the invention, growth factor described in the composition is selected from recombined human liver
Growth factor, hyperglycemic factor or PGE2.
In some specific embodiments of the invention, the dosage of composition is between umbilical cord described in the composition
Mesenchymal stem cells are calculated as 1.0~10.0 × 107/ kg the weight of animals.
The medicine and/or health products of prevention and/or treatment liver diseases are being prepared present invention also offers the composition.
The liver diseases are selected from by ischaemic, medicine such as paracetamol, virus, obesity nonalcoholic fatty liver disease,
Chronic liver injury caused by obstruction bile duct obstruction, tumour, hepatic failure, or chronic liver failure.
Additionally, present invention also offers a kind of medicine and/or health products for preventing and/or treating liver diseases, its feature
It is, including the composition that the present invention is provided.
The invention provides a kind of composition, including growth factor, albumin and umbilical cord mesenchymal stem cells.Said composition
Hepatic failure can be prevented, slowed down chronic liver failure and be in progress and remove harmful toxicity.This cell composition is for preventing and/or controlling
Treat such as second phthalein amino phenols, virus, obesity nonalcoholic fatty liver disease and obstruction bile duct are hindered by ischaemic, medicine
Chronic liver injury caused by plug, tumour is effective.
Brief description of the drawings
In order to illustrate more clearly about the embodiment of the present invention or technical scheme of the prior art, below will be to embodiment or existing
The accompanying drawing to be used needed for having technology description is briefly described.
Fig. 1 shows control group flow cytomery result；
Fig. 2 shows sample group flow cytomery result；
Fig. 3 shows that pathological section shows result；Wherein, Fig. 3 (A) shows normal group；Fig. 3 (B) shows control group；
Fig. 4 shows life cycle result.
Specific embodiment
The invention discloses a kind of composition and its application, those skilled in the art can use for reference present disclosure, suitably change
Enter technological parameter realization.In particular, all similar replacements and change are for a person skilled in the art aobvious
And be clear to, they are considered as being included in the present invention.The method of the present invention and application are carried out by preferred embodiment
Description, related personnel can substantially be carried out not departing from present invention, spirit and scope to method described herein and application
Change or suitably change with combining and realize and apply the technology of the present invention.
Raw materials used and reagent can be bought by market in the composition of present invention offer and its application.
With reference to embodiment, the present invention is expanded on further：
The umbilical cord mesenchymal stem cells of embodiment 1 are isolated and purified
Separate
Aseptic to take Healthy People fetal cord 10cm, soaking disinfection 5min in 75% ethanol solution is rinsed 2 times with PBS.Separate
And umbilical cord adventitia and blood vessel are taken out, and umbilical cord Wharton glue tissue shears are broken to 1mm3 tissue blocks, it is 0.1% to move to mass fraction
In clostridiopetidase A IV, cell suspending liquid is passed through 37 DEG C of digestion 18h 70 μm of cell filtering net.Cell suspension is collected with centrifuge tube,
With culture medium cyclic washing 2 times, centrifugation.With the DMEM-F12 culture medium re-suspended cells containing 10%FBS, and adjust cell density and be
2×105/ ml is inoculated into 15 ㎝ culture dishes, be transferred to 5%CO2,37 DEG C, cultivate in the CO2 incubators that saturated humidity is 95%.
Liquid is changed in cell culture after 6~7 days, hereafter 3d changes liquid once, until cell growth to degrees of fusion up to 85%, pancreatin had digestive transfer culture or
Freeze.This is primary umbilical cord mesenchymal stem cells.
Secondary Culture：After first all suctioning out nutrient solution during passage, wash secondary with PBS, add 37 DEG C the 0.25% of preheating
(2.5g/L) trypsase (EDTA containing 1mmol/L is prepared with 1mmol/L-EDTA-Na2) is digested 2 minutes, and addition is trained completely
Nutrient solution terminates pancreatin effect.Be collected in cell in 15ml centrifuge tubes after blowing and beating repeatedly by suction pipe, after 1500r/min is centrifuged 10 minutes
Supernatant is abandoned, then is washed with PBS liquid and secondary is thoroughly washed away the trypsase being mixed with.Cell is resuspended in nutrient solution, by 2~5
×105/ ml is inoculated with passes in new blake bottle again.When these cell growths are close to 80% fused layer, that is, obtain next
For umbilical cord MSC.
Umbilical cord mesenchymal stem cells amplification cultivation
Cell concentration is adjusted to 2~5 × 10 with L-DMEM complete culture solutions5/ ml culture umbilical cord mesenchymal stem cells are thin
Born of the same parents.In 5%CO2 incubators, after passing on 2 times, identify that umbilical cord mesenchymal stem cells and trypan blue count test with flow cytometry
Cell viability.
The identification of umbilical cord mesenchymal stem cells：
Take the 3rd generation cell, cell culture to when fusion, 0.25% Trypsin Induced 2min, with containing 5%FBS
Cold PBS rinse 2 times, add 1ml 0.01mol/LPBS resuspended, cell is gently blown and beaten repeatedly, make it into single cell suspension, plus
Enter CD106, CD29, CD44, CD45, CD19, CD34, HLA-DR mouse anti-human monoclonal's antibody, while making homotype pair with mouse IgG
According to, lucifuge is incubated 1h, after PBS washes 3 times, up flow type detection.Add 1ml 0.5% paraformaldehydes-PBS solution to fix, it is resuspended thin
Born of the same parents, flow cytometer detection.Umbilical cord mesenchymal stem cells after isolating and purifying show that its activity can reach through Trypan Blue
To 92%~95%, through flow cytomery, it was demonstrated that the purity for isolating and purifying the umbilical cord mesenchymal stem cells cell of amplification can
Up to more than 95%.
Embodiment 2 builds rat chronic hepatic failure model
With intraperitoneal injection Carbon Tetrachloride Induced rat chronic hepatic failure model, carbon tetrachloride is according to 4:6 are dissolved in vegetable oil.
Healthy week old adult male SD rats 60 are chosen, body weight (200 scholar 20) g is randomly divided into 4 groups：Normal group (25), model group
(25), cell composition treatment group (20) and physiological saline group (20).Model group, cell composition treatment group and physiology
Salt solution group is used and contains 40%CCl4Vegetable oil solution 1ml/kg body weight carry out intraperitoneal injection, every three days injection once, even
It is continuous 7 weeks, induce model group rats chronic liver failure.Normal group carries out intraperitoneal injection using vegetable oil 1ml/kg body weight, often
Every injection in three days once, week for 7 weeks.After modelling 7 weeks, randomly select normal group and model group rats each 5 only with it is complete from
Automatic Biochemical Analyzer detects serum and level to observe mouse liver function damage situations, the pathology of basis of microscopic observation mouse liver
Change.After modeling, AST and ALT water average specific normal group is significantly raised in model group mice serum；Pathological section shows, model
There is oedema, vacuole, massive inflammatory cells infiltrated in group murine liver tissue, and has wall regeneration, with its morphology and life
Change index performance to be consistent, then judge chronic liver failure modelling success.
Liver Function index serum ALB, ALT, AST and prothrombin time PT levels after the modeling of table 1
| AST | ALT | ALB | PT(s) | |
| Normal group | 27.11±15.07 | 157.51±26.67 | 38.95±7.42 | 20.87±6.84 |
| Model group | 283.49±37.22▲ | 592.16±56.13▲ | 17.91±2.58▲ | 38.08±7.60▲ |
▲ P ＜ 0.05vs normal groups；
Rat blood serum ALT (ALT) and aspartate aminotransferase (AST) substantially rise after modeling
Height, ALB is significantly lower than control group (P ＜ 0.05).
The preparation of the umbilical cord mesenchymal stem cells composition of embodiment 3
By flow cytometry identification and Trypan Blue, purity is more than 90% and sum reaches 107Umbilical cord between fill
Matter stem cell, centrifugation removal supernatant, plus injection physiological saline is cleaned 1~2 time, 400g centrifugation 5min, collects cell；
According to 15% (w/w) albumin, 30 μ g/ml HGFs, 4 μ g/ml PGE2s
(prostaglandin E2, PGE2), 20U/ml insulin, 3mg/ml hyperglycemic factors, 1.5 × 107The navel of/kg rat body weights
The umbilical cord mesenchymal stem cells composition that is made 1ml is resuspended in injection physiological saline with mescenchymal stem cell.
The preparation of the umbilical cord mesenchymal stem cells composition of embodiment 4
By flow cytometry identification and Trypan Blue, purity is more than 90% and sum reaches 107Umbilical cord between fill
Matter stem cell, centrifugation removal supernatant, plus injection physiological saline is cleaned 1~2 time, 400g centrifugation 5min, collects cell；
According to 40 μ g/ml HGFs, 6 μ g/ml prostaglandins, 30U/ml insulin, 5mg/ml pancreas hyperglycaemia
Element, 20% (w/w) albumin, 1.0 × 107The umbilical cord mesenchymal stem cells of/kg rat body weights are resuspended in injection physiological saline
In be made the umbilical cord mesenchymal stem cells composition of 1ml.
The preparation of the umbilical cord mesenchymal stem cells composition of embodiment 5
By flow cytometry identification and Trypan Blue, purity is more than 90% and sum reaches 107Umbilical cord between fill
Matter stem cell, centrifugation removal supernatant, plus injection physiological saline is cleaned 1~2 time, 400g centrifugation 5min, collects cell；
According to 60 μ g/ml HGFs, 8 μ g/ml prostaglandins, 40U/ml insulin, 6mg/ml pancreas hyperglycaemia
Element, 30% (w/w) albumin, 10 × 107The umbilical cord mesenchymal stem cells of/kg rat body weights are resuspended in injection physiological saline
It is made the umbilical cord mesenchymal stem cells composition of 1ml.
The tail vein of embodiment 6 is transplanted
Modeling carries out stem cell composition (3~embodiment of embodiment 5 is obtained) transplanting, after rat anesthesia, sterilization after 7 weeks
Afterbody, gives injection in stem cell composition 1ml injection transplantations, 3-5min and finishes by tail vein.Saline control group and
Normal group is used to same volume physiological saline tail vein.
The main pharmacodynamics result of study of embodiment 7
After ordinary circumstance modeling, model group rats engender loss of appetite, and behavior is blunt and stimulation is quick on the draw
The behaviouristics such as degree decline change.But compared with model group, by after stem cell composition of the present invention treatment, the dietary amount of rat has
Improved, above-mentioned symptom substantially mitigates, and the effect of stem cell composition of the present invention (embodiment 3~5 is obtained) is more obvious.
Importantly, not finding the adverse reaction related to stem cell over the course for the treatment of.
Packet situation：
Normal group：Normal group carries out tail vein injection using physiological saline 1ml；
Model group：Model group carries out tail vein injection using physiological saline 1ml；
Growth factor control group：The same model group of modeling method, gives after 7 weeks to tail vein in modeling and contains 30% (v/v)
Albumin, 60 μ g/ml HGFs, 4 μ g/ml prostaglandins, 40U/ml insulin, the life of 6mg/ml hyperglycemic factors
Reason salt solution 1ml carries out tail vein injection,
Stem cell group：The same model group of modeling method, gives embodiment 3~5 obtained combination after modeling 7 weeks to tail vein
(stem cell group 1 gives composition obtained in embodiment 3 to thing, and stem cell group 2 gives composition obtained in embodiment 4, stem cell group
3 give composition obtained in embodiment 5) 1ml carries out tail vein injection.
The influence (g/ days) of the rat diet amount of table 2
▲ P ＜ 0.05vs blank groups；△ P ＜ 0.05vs model groups；★ P ＜ 0.05vs growth factor groups；
Record rat diet, activity, to IR, fur gloss, depilation situations such as.Using comprehensive grading standard determination
It is as follows:Movable normal (3 points of note) is 3~5 times/min, and it is 1~2 time/min that activity reduces (2 points of note), and inertia (1 point of note) is<
1 time/min.Be quick on the draw (remember 3 points) is to be rapidly converting to tap sound direction and with limb motion, reaction to beaing cage wall sound
It is only to turn to percussion sound direction to beaing cage wall sound to weaken (2 points of note), and (1 point of note) slow in reacting is to tapping cage wall sound only
Open eyes or come back.
As a result：
Normal rats are flexible, and reaction is sensitive, diet is normal, and fur light is submissive.Rat modeling after 1 month it is more normal
Group and sham-operation group are slightly worse, and postoperative 21d appearance activity is reduced, and IR weakens to external world, and burnout is One's spirits are drooping, postoperative 28d
Then above-mentioned performance is aggravated, and each basic inertia of rat is slow in reacting, and fur is confused and disordered, come off, easily concurrent various infection diseases.
Each group activities in rats and reaction scoring situation are shown in Table 3.
The activities in rats of table 3 and reaction comprehensive grading compare
▲ P ＜ 0.05vs blank groups；△ P ＜ 0.05vs model groups；★ P ＜ 0.05vs growth factor groups；
Life cycle as shown in figure 4, analyzed by Kaplan-Meier, mean survival time of model group is 4.65 months,
The mean survival time of growth factor control group is 5.15 months, and the mean survival time of stem cell group of the present invention is 5.81
Month, while being pointed out by Chi-square Test, the Cumulative survival rate of stem cell group of the present invention is higher than model group and physiological saline group, difference
It is statistically significant.
Liver function and coagulation function
Normal group：Normal group carries out tail vein injection using physiological saline 1ml；
Model group：Model group carries out tail vein injection using physiological saline 1ml；
Growth factor control group：The same model group of modeling method, gives after 7 weeks to tail vein in modeling and contains 20% (v/v)
Albumin, 150 μ g/kg HGFs, 20 μ g/kg PGE2s (prostaglandin E2, PGE2), 0.1U/
Kg insulin, the physiological saline 1ml of 15 μ g/kg hyperglycemic factors carry out tail vein injection,
Stem cell group：The same model group of modeling method, gives embodiment 3~5 obtained combination after modeling 7 weeks to tail vein
(stem cell group 1 gives composition obtained in embodiment 3 to thing, and stem cell group 2 gives composition obtained in embodiment 4, stem cell group
3 give composition obtained in embodiment 5) 1ml carries out tail vein injection.
The results are shown in Table 4.
Table 4
▲ P ＜ 0.05vs blank groups；△ P ＜ 0.05vs model groups；★ P ＜ 0.05vs growth factor groups；
As shown in table 4, after intraperitoneal injection CCl4 week for 7 weeks, model group rats Serum ALT, AST, TBIL and PT level show
Write raise, while serum ALB, CHE level is remarkably decreased, compare with blank group, difference it is statistically significant and pass through this hair
After bright stem-cell therapy, Serum ALT, AST, TBIL and PT level are remarkably decreased, while serum ALB, CHE level significantly rises,
Compared with model group and physiological saline group, difference is statistically significant.
Hepatic tissue pathology scores
Normal group：Normal group carries out tail vein injection using physiological saline 1ml；
Model group：Model group carries out tail vein injection using physiological saline 1ml；
Growth factor control group：The same model group of modeling method, gives after 7 weeks to tail vein in modeling and contains 20% (v/v)
Albumin, 150 μ g/kg HGFs, 20 μ g/kg PGE2s (prostaglandin E2, PGE2), 0.1U/
Kg insulin, the physiological saline 1ml of 15 μ g/kg hyperglycemic factors carry out tail vein injection,
Stem cell group：The same model group of modeling method, gives embodiment 3~5 obtained combination after modeling 7 weeks to tail vein
(stem cell group 1 gives composition obtained in embodiment 3 to thing, and stem cell group 2 gives composition obtained in embodiment 4, stem cell group
3 give composition obtained in embodiment 5) 1ml carries out tail vein injection.Cut into slices under light microscopic and scored, hepar damnification is by necrosis or becomes
The quantity of property cell is divided into six grades of classifications, and specific standards are as follows：
0 grade：Not damaged；
1 grade：Slight damage, it is seen that point-like or fraction necrosis of liver cells；
2 grades：Minor injury, it is seen that 10~25% necrosiss of liver cells are dispersed in slight denaturation；
3 grades：Moderate lesion, it is seen that 25~40% necrosiss of liver cells or denaturation；
4 grades：Substantially damage, it is seen that 40~50% necrosiss of liver cells or denaturation；
5 grades：Major injury, >=50% necrosis of liver cells or denaturation.
Histology sxemiquantitative scoring statistics uses Chi-square Test, and the promptings of P ＜ 0.05 difference is statistically significant.
The results are shown in Table 5.
Table 5
| Group | n | Pathological lesion is integrated |
| Blank group | 20 | 0 |
| Model group | 20 | 2.28±0.75* |
| Growth factor control group | 20 | 2.46±0.87* |
| Stem cell group 1 | 20 | 1.17±0.62*△ |
| Stem cell group 2 | 20 | 1.42±0.55*△ |
| Stem cell group 3 | 20 | 1.89±0.64*△ |
*P ＜ 0.05vs blank groups；△ P ＜ 0.05vs model groups
As shown in table 5, after intraperitoneal injection CCl4 week for 7 weeks, model group and saline rats hepatic tissue pathology are damaged
Integration highest, after being treated through stem cell composition of the present invention (obtained in embodiment 3~5), pathological lesion integration is remarkably decreased, with
Model group is compared, and difference is statistically significant.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of composition, it is characterised in that including growth factor, albumin and umbilical cord mesenchymal stem cells.
2. composition according to claim 1, it is characterised in that the growth factor is selected from HGF, preceding
Row parathyrine, insulin or hyperglycemic factor.
3. composition according to claim 1 and 2, it is characterised in that the HGF accounts for containing for composition
Measure as 30 μ g/ml~60 μ g/ml, the prostaglandin account for the content of composition for 4 μ g/ml~8 μ g/ml, the insulin are accounted for
The content of composition is that the content that 20U/ml~40U/ml, the hyperglycemic factor account for composition is 3mg/ml~6mg/ml.
4. the composition according to any one of claims 1 to 3, it is characterised in that the albumin accounts for the quality of composition
Percentage composition is 15~30%.
5. the composition according to any one of Claims 1-4, it is characterised in that the albumin accounts for the quality of composition
Percentage composition is 20%.
6. the composition according to any one of claim 1 to 5, it is characterised in that the umbilical cord mesenchymal stem cells it is dense
Spend is 1.0~10.0 × 107/ml。
7. the composition according to any one of claim 1 to 6, it is characterised in that the umbilical cord mesenchymal stem cells it is dense
Spend is 1.5 × 107/ml。
8. the composition according to any one of claim 1 to 7, it is characterised in that the dosage of the composition is with navel
Band mescenchymal stem cell is calculated as 1.0~10.0 × 107/ kg the weight of animals.
9. the composition according to any one of claim 1 to 8 prepare prevention and/or treatment liver diseases medicine and/
Or health products.
10. it is a kind of prevent and/or treatment liver diseases medicine and/or health products, it is characterised in that including such as claim 1
To the composition described in 8 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611220181.4A CN106729641A (en) | 2016-12-26 | 2016-12-26 | Composition and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611220181.4A CN106729641A (en) | 2016-12-26 | 2016-12-26 | Composition and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106729641A true CN106729641A (en) | 2017-05-31 |
Family
ID=58927051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611220181.4A Pending CN106729641A (en) | 2016-12-26 | 2016-12-26 | Composition and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106729641A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106692951A (en) * | 2016-12-26 | 2017-05-24 | 广州赛莱拉干细胞科技股份有限公司 | Composition and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103585177A (en) * | 2012-08-13 | 2014-02-19 | 首都医科大学附属北京口腔医院 | Applications of mesenchymal stem cell and genetically modified mesenchymal stem cell |
| CN105056303A (en) * | 2015-09-21 | 2015-11-18 | 广州赛莱拉干细胞科技股份有限公司 | Composition, preparation and application thereof |
| CN105534848A (en) * | 2015-12-29 | 2016-05-04 | 四川新生命干细胞科技股份有限公司 | Cosmetic or pharmaceutical composition and application thereof |
-
2016
- 2016-12-26 CN CN201611220181.4A patent/CN106729641A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103585177A (en) * | 2012-08-13 | 2014-02-19 | 首都医科大学附属北京口腔医院 | Applications of mesenchymal stem cell and genetically modified mesenchymal stem cell |
| CN105056303A (en) * | 2015-09-21 | 2015-11-18 | 广州赛莱拉干细胞科技股份有限公司 | Composition, preparation and application thereof |
| CN105534848A (en) * | 2015-12-29 | 2016-05-04 | 四川新生命干细胞科技股份有限公司 | Cosmetic or pharmaceutical composition and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106692951A (en) * | 2016-12-26 | 2017-05-24 | 广州赛莱拉干细胞科技股份有限公司 | Composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109880797A (en) | A method of preparing human umbilical cord mesenchymal stem cells excretion body | |
| CN105861430A (en) | Exosome, preparing method of exosome and application of exosome in preparing medicine or preparation for treating sepsis | |
| CN106754674A (en) | Method and its application of amnion mesenchymal stem cell are prepared from Human plactnta amnion | |
| CN104719282A (en) | Peripheral blood mononuclear cell serum-free freezing medium and freezing method | |
| CN106421920B (en) | A kind of fat filler and preparation method thereof | |
| JP2020191861A (en) | Umbilical cord mesenchymal stem cells mscs and culture methods and applications thereof | |
| CN106801032B (en) | Construction method of human amniotic epithelial stem cell bank | |
| CN104762259A (en) | Culture medium for mesenchymal stem cells and large-scale culture method thereof | |
| CN105154395A (en) | Preparing method for clinic level cells for enhancing immune modulating function of MSCs | |
| CN105670986A (en) | Culture medium for inducing human umbilical cord mesenchymal stem cells to differentiate into islet-like cells and induction method therefor | |
| CN104762257B (en) | A kind of method preparing mescenchymal stem cell from umbilical cord | |
| CN104673745A (en) | Isolated culture method of porcine fat stem cells | |
| CN106434557A (en) | Method for preparing CD34 positive cells from umbilical cord mesenchymal stem cells | |
| CN104450611A (en) | Primary separation and culture method of human amniotic mesenchymal stem cells | |
| CN104726406A (en) | Method for inducing dental pulp mesenchymal stem cells to be differentiated into nerve cells | |
| CN103074298A (en) | Human fat mesenchymal stem cell bank and construction method thereof | |
| CN109646458B (en) | Method for treating scleropathy using placental mesenchymal stem cell preparation | |
| CN102517251A (en) | Mesenchymal stem cells, as well as preparation method and application thereof | |
| CN107189982A (en) | A kind of cultural method of human umbilical cord mesenchymal stem cells | |
| CN108192862A (en) | A kind of preparation method of pilose antler stem cell, pilose antler stem cell and its application | |
| CN105238749A (en) | Method for resuscitating mesenchymal stem cells | |
| CN102851255A (en) | Efficient and fast method for separating mesenchymal stem cells | |
| CN106566803A (en) | Culture solution, application of culture solution and method for culturing umbilical cord mesenchymal stem cells | |
| CN103301154A (en) | Application of umbilical cord mesenchymal stem cells in preparation of formulation for treating lupus erythematosus | |
| CN109825469A (en) | A kind of promotion abductive approach of the source of people umbilical cord mesenchymal stem cells to Chondrocyte Differentiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |